Evaluation of the correlation of caspofungin MICs and treatment outcome in murine infections by wild type strains of Candida parapsilosis

Diagnostic Microbiology and Infectious Disease

Volumn 77, Issue 1, 2013, Pages 41-45

  Salas, Valentina ^a   Pastor, F Javier ^a   Capilla, Javier ^a   Sutton, Deanna A ^b   Mayayo, Emilio ^a   Fothergill, Annette W ^b   Rinaldi, Michael G ^b   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Animal models; C. parapsilosis; Caspofungin; Fungal infections

Indexed keywords

BETA GLUCAN; CASPOFUNGIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA PARAPSILOSIS; CANDIDIASIS; CONTROLLED STUDY; DISK DIFFUSION; DRUG EFFICACY; FUNGAL STRAIN; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; WILD TYPE;

EID: 84881542125     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.05.011     Document Type: Article

References (26)

1. Andes D., Diekema D.J., Pfaller M.A., Bohrmuller J., Marchillo K., Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010, 54:2497-2506.
2. Arendrup A.C., Perlin D.S., Jensen R.H., Howard S.J., Goodwin J., Hope W. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations. Antimicrob Agents Chemother 2012, 56:2435-2442.
3. Barchiesi F., Spreghini E., Tomassetti S., Della Vittoria A., Arzeni D., et al. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob Agents Chemother 2006, 50:2719-2727.
4. Budhavari S. What's new in diagnostics? Fungitell®: 1,3 Beta-D glucan assay. South Afr J Epidemiol Infect 2009, 24:37-38.
5. Cantón E., Espinel-Ingroff A., Pemán J., del Castillo L. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 2010, 54:2194-2197.
6. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition, M7-A3 2008, CLSI, Wayne, PA.
7. Clinical and Laboratory Standards Institute (CLSI) Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline, M4A-A2 2008, CLSI, Wayne, PA.
8. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK- 0991(L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998, 36:2950-2956.
9. Földi R., Kovács R., Gesztelyi R., Kardos G., Berényi R., Juhász B., et al. Comparison of in vitro and in vivo efficacy of caspofungin against Candida parapsilosis, C orthopsilosis, C. metapsilosis and C. albicans. Mycopathologia 2012, 174:311-318.
10. Fujita S., Takamura T., Nagahara M., Hashimoto T. Evaluation of a newly developed down flow for detection of serum mannan antigens in patients with candidaemia. J Med Microbiol 2006, 55:537-543.
11. Garcia-Effron G., Katiyar S.K., Park S., Enlind T.D., Perlin D.S. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 2008, 52:2305-2312.
12. Kartsonis N., Killar J., Mixson L., Hoe C.M., Sable C., Bartizal K., et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005, 49:3616-3623.
13. Ortoneda M., Capilla J., Pastor F.J., Serena C., Guarro J. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004, 50:247-251.
14. Ostrosky-Zeichner L. Invasive mycoses: diagnostic challenges. Am J Med 2012, 125(Suppl. 1):S14-S24.
15. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
16. Pazos C., Moragues M.D., Quindós G., Pontón J., del Palacio A. Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients. Rev Iberoam Micol 2006, 23:209-215.
17. Pemán J., Zaragoza R. Towards an early diagnosis of invasive candidiasis in the critically ill patients. Rev Iberoam Micol 2012, 29:71-75.
18. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010, 48:52-56.
19. Pfaller M.A., Diekema D.J. Progress in antifungal susceptibility testing of Candida spp. using Clinical and Laboratory Standards Institute broth microdilution methods, 2010-2012. J Clin Microbiol 2012, 50:2846-2856.
20. Pfaller M.A., Diekema D.J., Andes D., Arendrup M.C., Brown S.D., Lockhart S.R., et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretative criteria. Drug Resist Updat 2011, 14:164-176.
21. Pfaller M.A., Moet G.J., Messer S.A., Jones R.N., Castanheira M. Candida bloodstream infections: comparison of species distribution and antifungal resistance in community onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 2011, 55:561-566.
22. Spreghini E., Orlando F., Tavanti A., Senesi S., Giannini D., Manso E., et al. In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother 2012, 67:2195-2202.
23. Sun H.Y., Chiu Y.S., Tang J.L., Wang J.L., Chang S.C., Chen Y.C. The usefulness of the Platelia Candida antigen in a patient with acute lymphocytic leukemia and chronic disseminated candidiasis. Med Mycol 2006, 44:647-650.
24. Trofa D., Gácser A., Nosanchuk J.D. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008, 21:606-625.
25. Ullmann A.J., Akova M., Herbretch R., Viscoli C., Arendrup M.C., Arikan-Akdagli S., et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012, 18(Suppl. 7):53-67.
26. van Asbeck E.C., Clemons K.V., Stevens D.A. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit Rev Microbiol 2009, 35:283-309.